3 ms·
Your summary is incorrect. Lowe's position is stated at http://blogs.sciencemag.org/pipeline/archives/2018/05/25/federal-right-to-try http://blogs.sciencemag.or
by eesmith 8y ago
Your summary is incorrect. Lowe's position is stated at http://blogs.sciencemag.org/pipeline/archives/2018/05/25/federal-right-to-try http://blogs.sciencemag.org/pipeline/archives/2018/05/25/fed... . He writes:
> I think Right to Try laws are largely useless, and have the potential to cause actual harm disproportionate to the good they might do. I think that there are sincere, principled advocates for them, but at the same time, there are many people on that side of the issue who are either ill-informed about medical research or who are simply grandstanding for votes and popular support.
> In short, my biggest reasons for thinking this way are: (1) most investigational drugs don’t work. The failure rate in human clinical trials is around 90 per cent, and it’s been that way for a long time. (2) there are disease areas where a tragedy-of-the-commons situation will mean that controlled clinical trials (which are still the only way to determine if a new drug works) will be much more difficult to run under a “why wait for proof?” system (I have to note that the current bill restricts right-to-try to those patients who are ineligible for clinical trials, which is a good provision). (3) opening up unproven therapies could lead to a moral hazard, where it becomes lucrative to put useless-but-harmless “drug candidates” into “clinical trials” so you can charge desperate patients at “cost”. I mean every quotation mark in that last sentence. I am not the only person who thinks this way. My own suggestion for the last point has already been made: antioxidant phytonutrients – i.e., dried grape juice pills – for Alzheimer’s. Won’t do a thing, but hey, you have the right to try ’em.
> There is empirical evidence for all of these positions. Many states have passed their own right-to-try laws (in various forms), and if there has been any decrease in human suffering or advance in medical knowledge through them, I have missed it. To get specific, when Colorado passed its own law in 2014, one of the first companies that announced plans to offer treatments under its provisions was a stem-cell company, Neuralstem. And guess what? None of their treatments ever worked. Most things don’t.
Note that Lowe talked about harm which is disproportionate to the good, not the un-nuanced statement that that there may be harm and therefore bad, as you summarized it.
- Jach 8y ago>> controlled clinical trials (which are still the only way to determine if a new drug works) His objections are good, but this mindset will probably have to go in order to make headway on more efficient medicine. It would also alleviate the concern in #3, because once you give up that mindset, you actually have tools besides the (expensive) controlled clinical trial that allow you to make statements like "dried grape juice pills won't do a thing for Alzheimer's".
- eesmith 8y agoDo you have any examples of alternative methods to determine if a new drug works, or is this simply an expression of optimism? The pharmaceutical industry would pay billions for a cheaper or more effective replacement.
- Jach 8y agoThe main alternative method I had in mind was that of causal inference. I can't recall seeing a very detailed paper of its effectiveness at judging a drug from observational data rather than a controlled (and expensive) clinical study but I'm sure it's been done, it's used in a number of areas in medicine and the social sciences. But it's more sophisticated than the classical battery of statistical tests you get to use if you design a classical clinical trial. However it works with clinical trials too -- it would probably help out with the replication crisis... The other method I had in mind is to put more focus on basic theory / models. Models in the sense of individual elements that can take input and produce output, not aggregated statistical models. These models can inform (and be informed by) later data. They're pretty useful with and without controlled experiments, e.g. either particle physics or astronomy. When applied to drugs, a functional model of how a drug would interact with the organism will tell you whether a drug works or not -- clinical trials and observation both can help refine the model as its outputs match up against reality. Of course good models of biology are hard, many mechanisms are poorly understood, but you need more focus at this stage before you even consider getting to the clinical trial. Unfortunately less effort seems to be spent on the modeling, more effort on getting quick iterative feedback via petri dishes then animal studies, and then disappointment when something fails in expensive human trials. With a lot more focus on the modeling side, with more willingness to use the data from experiments that aren't "gold standard" controlled clinical trials and to use tools like causal analysis, is it unreasonable to imagine that a lot less money could be spent for a lot sounder results? I'm not sure we can conclude such broad things about what the pharmaceutical industry wants or would and would not do. It's a mess of a beast. With the side effect of astronomical costs that results from this mentality of thinking controlled clinical studies are always necessary and the only way to know for sure, and more directly that you need them for every new drug to get to market because of regulations, is it any wonder that most new drugs are "me-too" drugs that companies "researched" from existing drugs to be just different enough to earn a new patent and get past the clinical trials that its predecessors did so they can sell it and make a profit? (Rent-Seeking and Redundancy, http://levine.sscnet.ucla.edu/papers/imbookfinal09.pdf http://levine.sscnet.ucla.edu/papers/imbookfinal09.pdf)